VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 295 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2018. The put-call ratio across all filers is 2.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $1,686,000 | -61.9% | 105,920 | -65.7% | 0.07% | -58.9% |
| Q3 2017 | $4,420,000 | +139.6% | 308,500 | +189.1% | 0.18% | +125.0% |
| Q2 2017 | $1,845,000 | -47.4% | 106,704 | -66.4% | 0.08% | -47.4% |
| Q1 2017 | $3,506,000 | -3.2% | 317,899 | +27.4% | 0.15% | -29.6% |
| Q4 2016 | $3,621,000 | +4.8% | 249,435 | +77.3% | 0.22% | -7.7% |
| Q3 2016 | $3,454,000 | -55.5% | 140,719 | -63.5% | 0.23% | -54.9% |
| Q2 2016 | $7,769,000 | +17.7% | 385,788 | +53.7% | 0.52% | -1.3% |
| Q1 2016 | $6,600,000 | -67.3% | 250,955 | +26.2% | 0.53% | -66.8% |
| Q4 2015 | $20,207,000 | +523.7% | 198,799 | +994.2% | 1.58% | +564.7% |
| Q3 2015 | $3,240,000 | +64.8% | 18,168 | +105.3% | 0.24% | +44.2% |
| Q2 2015 | $1,966,000 | +159.0% | 8,851 | +131.4% | 0.16% | +87.5% |
| Q1 2015 | $759,000 | -66.0% | 3,825 | -75.5% | 0.09% | -67.5% |
| Q4 2014 | $2,234,000 | – | 15,613 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |